PCLS: 8-lncRNA Prognostic Signature for Liver Cancer

An 8-lncRNA prognostic signature (PCLS) constructed from TCGA data stratifies hepatocellular carcinoma patients into risk groups. The signature likely contains risk scores and associated clinical outcomes, predicting differential responses to immunotherapy and chemotherapy. Author Changguang Lv uploaded the dataset on figshare under a CC-BY-4.0 license.

Use Cases

• Stratifying hepatocellular carcinoma patient risk based on an 8-lncRNA signature.
• Predicting patient response to immunotherapy based on tumor microenvironment features.
• Guiding personalized chemotherapy strategies using the PCLS risk score.
• Investigating the role of palmitoylation-coexpressed lncRNAs in cancer progression.

Strengths

• Signature was constructed via LASSO and multivariate Cox regression, suggesting a rigorous statistical method.
• The model robustly stratified patients into risk groups with distinct overall survival outcomes.
• Dataset is openly available under a permissive CC-BY-4.0 license.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect bias inherent to the TCGA source and figshare platform.

Provenance

Source

TCGA (The Cancer Genome Atlas)

Collection Method

Constructed via LASSO and multivariate Cox regression analysis.

Freshness

Last updated 2026-06-03 12:02:03; freshness should be verified.